Report predicts pharma growth through and beyond pandemic

16 July 2020

A new report has predicted that the pharmaceutical industry will continue to thrive, despite the short-term damage done to sales by the COVID-19 pandemic.

According to the EvaluatePharma World Preview 2020, Outlook to 2026, the impact of COVID-19 has so far wiped $7.85 billion off forecasts for biopharma sales in 2020, with the top 15 companies bearing 60% of that loss.

However, the industry is predicted to remain in good health overall, with prescription drug sales growing 3.7% in 2020 to $904 billion and reaching almost $1.4 trillion in 2026.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK